Background-Activation of both type 1 and type 2 tumor necrosis factor (TNF) receptors (TNFR1 and TNFR2) confers cytoprotection in cardiac myocytes. Noting that the scaffolding protein TNF receptor-associated factor 2 (TRAF2) is common to both TNF receptors, we hypothesized that the cytoprotective responses of TNF were mediated through TRAF2.
P revious studies have shown that the adult mammalian heart synthesizes an ensemble of proteins that modulate cardiac repair and remodeling after myocardial infarction and/or ischemia-reperfusion (IR) injury (reviewed in reference 1). Recently, we and others have suggested that cytokines belonging to the innate immune system, a phylogenetically conserved host defense system, play a critical upstream role in terms of orchestrating the early myocardial response to tissue injury. Cytokines that comprise the innate stress response in the heart include tumor necrosis factor (TNF), interleukins-1, -6, and -18, cardiotrophin-1, and leukemia inhibitory factor. Although sustained overexpression of these molecules is sufficient to provoke left ventricular (LV) dysfunction and LV remodeling, and can thus lead to overt cardiac decompensation, 1 there is increasing evidence suggesting that this same family of proteins plays an important role in limiting myocardial cell injury, at least in part, by conferring cytoprotective responses in cardiac myocytes (reviewed in reference 1). Previous studies have shown that TNF confers cytoprotective responses in the adult heart after coronary artery ligation and IR injury. [2] [3] [4] [5] [6] [7] However, the mechanisms that are responsible for the cytoprotective effects of TNF are not known. Germane to this discussion is the observation that mice lacking both TNF receptors type 1 (TNFR1) and type 2 (TNFR2) have an increase in infarct size after acute ligation of the left tline anterior descending artery, whereas infarct size was similar to the wild type in both TNFR1-and TNFR2-deficient mice. 4 Moreover, gain of function studies have shown that activation of TNFR1 or TNFR2 confers cytoprotection in adult cardiac myocytes subjected to hypoxia/reoxygenation injury. 2 Viewed together, these results suggest that the cytoprotective effects of TNF are conveyed through TNFR1 and/or TNFR2. Although it is conceivable that TNFR1 and TNFR2 activate disparate cytoprotective signal transduction pathways, the most parsimonious explanation for these experimental observations is that TNFR1 and TNFR2 transduce a common cytoprotective repertoire in the heart. Noting that the intracellular scaffolding protein TNF receptor-associated factor 2 (TRAF2) was common to both TNFR1 and TNFR2, and recognizing that TRAF2 mediates cytoprotection in nonmyocyte cell types, 8 we hypothesized that the cytoprotective effects of TNF in the heart were mediated, at least in part, through TRAF2. To test this hypothesis, we have generated lines of transgenic mice that overexpress TRAF2 in the cardiac compartment. We show, through both gain and loss of function approaches, that endogenous TNF signaling confers cytoprotection in the heart after IR injury ex vivo and present the novel finding that TRAF2 is sufficient to phenocopy the cytoprotective effects of TNF in the heart after IR injury.
Methods

Generation and Characterization of Transgenic and Knockout Mice
MHCsTNF 3 Transgenic Mice
The hemizygous line of transgenic mice with cardiac-restricted overexpression of low levels of TNF (referred to as MHCsTNF 3 ) has been described elsewhere in detail (C57BL/6ϫICR background). 9 In brief, these mice develop mild concentric hypertrophy by 8 weeks of age. However, in contrast to transgenic lines with high levels of expression of TNF, 10 the MHCsTNF do not develop LV dilation or LV dysfunction. The observation that lower levels of TNF expression lead to a milder cardiac phenotype is consistent with the observation by Higuchi et al, 11 who showed that the adverse cardiac phenotype of high levels of TNF expression is attenuated in mice with a genetic deletion of the TNFR1. Littermate (LM) controls lacking the TNF transgene were used as the appropriate controls.
TNFR1 ؊/؊ , TNFR2 ؊/؊ , and TNFR1/TNFR2 (TNFR1 ؊/؊ /TNFR2 ؊/؊ ) Null Mice
Mice deficient in TNFR1 (TNFR1 Ϫ/Ϫ ), TNFR2 (TNFR2 Ϫ/Ϫ ), or both TNF receptors (TNFR1 Ϫ/Ϫ /TNFR2 Ϫ/Ϫ ) were purchased from Jackson Laboratories (Bar Harbor, Maine). C57/BL6 wild-type mice were used as appropriate controls for the TNFR1 Ϫ/Ϫ and TNFR2 Ϫ/Ϫ , whereas B6129F2 wild-type mice were used as the appropriate controls for the TNFR1 Ϫ/Ϫ /TNFR2 Ϫ/Ϫ mice. The TNF receptor null mice exhibit a normal cardiac phenotype under baseline conditions. 4
MHC-TRAF2 Transgenic Mice
Mice with cardiac-restricted expression of TRAF-2 were generated for this study using the ␣-myosin heavy chain promoter (a gift from Jeff Robbins) to target murine TRAF2 to the cardiac myocyte (see online-only Data Supplement for details). 10 The MHC-TRAF2 mouse lines were characterized at 12 weeks of age using standard morphological and histological analyses, as described, 10 as well as 2D-targeted M-mode echocardiography and hemodynamics using Millar catheters (see Data Supplement).
TRAF2-mediated signaling leads to activation of nuclear factor-B (NF-B) and c-Jun N-terminal kinase (JNK). 12 Accordingly, we sought to determine whether these pathways were activated in the MHC-TRAF2 LC mice using electromobility gel shift assays to measure NF-B activation, an in-gel kinase assay to measure JNK activity (see Data Supplement for details). In preliminary control experiments (supplemental Figure I) , we determined that the basal level of TGF-␤-activated kinase-1 activity was minimal in the MHC-TRAF2 LC and LM control mice.
For all the studies reported herein, we used 10-to 12-week-old male mice. All mice were housed under standard environmental conditions and were fed commercial chow and tap water ad libitum. All studies conformed to the principles of the National Institutes of Health "Guide for the Care and Use of Laboratory Animals" and were approved by the Baylor College of Medicine Animal Care and Use Committee.
Effects of IR Injury
Isolated Heart Perfusion Studies
Hearts from MHCsTNF 3 , TNFR1 Ϫ/Ϫ , TNFR2 Ϫ/Ϫ , TNFR1 Ϫ/Ϫ / TNFR2 Ϫ/Ϫ , MHC-TRAF2, and their respective LM and/or wild-type controls were isolated and perfused in the Langendorff mode as previously described. 13 After a 30-minute stabilization period, hearts were subjected to no-flow ischemia (tϭ0 minutes) for 30 minutes followed by reperfusion (tϭ30 minutes) for up to 30 minutes (tϭ60 minutes). All hearts were paced at 420 bpm with pacing electrodes placed on the right atrium. Pacing was interrupted during ischemia and resumed 3 minutes after the start of reperfusion. Functional data were recorded at 1 kHz on a data acquisition system (PowerLab, ADInstruments, Colorado Springs, Colo). LV developed pressure (LVDP) was calculated as the difference between peak systolic pressure and LV end-diastolic pressure.
Creatinine Kinase Assay
Coronary effluent was collected on ice during the first 30 minutes of reperfusion in the hearts subjected to IR and during the last 30 minutes of perfusion in the control hearts. Creatine kinase (CK) activity was measured with a commercially available CK assay kit (Diagnostic Chemical, Charlottetown, Prince Edward Island, Canada) according to the manufacturer's recommendations. CK activity was normalized for frozen dry heart weight. Data are expressed as units per gram of cardiac tissue.
Evans Blue Staining
Because triphenyltetrazolium chloride staining may underestimate the true extent of tissue injury within the first 3 hours of cardiac injury, 14 we used Evans blue dye uptake to assess the degree of myocardial tissue injury after IR injury (see Data Supplement). Evans blue is a cell-impermeable diazo dye that has been used to study the integrity/permeability of blood vessels and cell membranes that become injured. In muscle cells with permeable membranes, Evans blue dye crosses into the cell and accumulates in myofibrils, where it emits red autofluorescence when examined using fluorescence microscopy. 15 Fluorescence microscopy (200ϫ) was performed using a filter set with an excitation of 510 to 560 nm and an emission of 590 nm to assess the amount of Evans blue dye uptake in the myocardium at baseline and after IR injury. Hearts were examined at the level of the papillary muscle using a total of 30 microscopic fields per heart. Data are expressed as the percent area of the myocardium with red fluorescence.
Statistical Analysis
Data are expressed as meanϮSEM. Two-way repeated-measures ANOVA was used to test percentage LVDP over time between groups. One-way ANOVA was used to test for differences in CK release after reperfusion in the TNFR1 Ϫ/Ϫ , TNFR2 Ϫ/Ϫ , and wildtype mice. Posthoc ANOVA testing was performed, when appropriate, using the Tukey test. CK release, the area of the myocardium (%) with Evans blue uptake after IR, and heart weight-to-body weight ratios were examined using a nonpaired t test. Significant differences were said to exist at PϽ0.05.
Results
Effect of Cardiac-Restricted Overexpression of TNF on IR Injury
To determine whether overexpression of low levels of TNF in the heart protects against IR injury, we subjected hearts from MHCsTNF 3 mice to 30 minutes of no-flow ischemia followed by 30 minutes of reperfusion. Baseline LVDP was not different in the MHCsTNF 3 and LM control hearts (data not shown). Figure 1A shows that LV functional recovery was significantly greater after IR injury in the MHCsTNF 3 mice compared with the LM control mice at 10, 20, and 30 minutes (PϽ0.05/time) of reperfusion. To determine whether the increased functional recovery of MHCsTNF 3 hearts subjected to IR injury was the result of decreased myocyte injury, we measured CK release and Evans blue dye uptake. There was a significant (PϽ0.05) 6-fold decrease in CK release 30 minutes after IR injury in the MHCsTNF 3 hearts compared with LM control hearts ( Figure 1B) . Similar findings were observed when Evans blue dye uptake was measured. As shown by the representative fluorescence photomicrographs ( Figure 1C ) and the results of group data ( Figure 1D ), there was a significant (PϽ0.05) decrease in Evans blue dye uptake in the hearts of the MHCsTNF 3 mice 30 minutes after IR injury. Viewed together, these results suggest that low levels of myocardial TNF protect cardiac myocytes against IR injury ex vivo.
Effect of Loss of Endogenous TNF Signaling on IR Injury
Acute coronary ligation results in increased cardiac myocyte cell death in TNF receptor null (TNFR1 Ϫ/Ϫ /TNFR2 Ϫ/Ϫ ) mice that lack endogenous TNF signaling. 4 To determine whether endogenous TNF receptor signaling was also important in the setting of IR injury, we performed isolated heart IR injury studies in TNF receptor null mice. Baseline LVDP was not different in the TNF receptor null mice and LM controls (data not shown). Figure 2A shows that LV functional recovery was significantly less at 10, 20, and 30 minutes after reperfusion injury (PϽ0.05/time) in the TNF receptor null mice compared with LM control mice. To determine whether this decrease in functional recovery was secondary, at least in part, to increased cardiac myocyte cell injury, we measured CK release and Evans blue dye uptake. There was a signifi-cant (PϽ0.05) 2-fold increase in CK release in the effluent of the reperfused TNF receptor null mice ( Figure 2B ) that was accompanied by a significant (PϽ0.05) increase in Evans blue dye uptake ( Figure 2C and 2D) compared with LM controls.
To determine which TNF receptors were responsible for the increased cell death in the TNFR null mice, we subjected hearts from TNFR1 Ϫ/Ϫ or TNFR2 Ϫ/Ϫ mice to 30 minutes no-flow ischemia followed by 30 minutes of reperfusion. Figure 3A shows that there was no significant difference (Pϭ0.60) in LV functional recovery in TNFR1 Ϫ/Ϫ or TNFR2 Ϫ/Ϫ hearts after IR injury compared with LM control hearts at 10, 20, and 30 minutes of reperfusion. Similarly, the amount of myocardial CK release from TNFR1 Ϫ/Ϫ or TNFR2 Ϫ/Ϫ mice subjected to IR injury was not significantly different (Pϭ0.90) compared with IR-injured LM control hearts ( Figure 3B ). Taken together, these results suggest that complete loss of endogenous TNF receptor signaling in the heart leads to increased myocyte cell injury and that endogenous signaling through either TNFR1 or TNFR2 is sufficient to protect against IR injury ex vivo.
Effects of Cardiac-Restricted Overexpression of TRAF2 on IR Injury
The results of the studies presented in Figures 1 and 2 suggest that TNF-mediated signaling confers a cytoprotective signal that is mediated either through TNFR1 or through TNFR2. Noting that TRAF2 was the only signaling molecule that was common to both TNF receptors, and recognizing that TRAF2-mediated signaling plays an important cytoprotective role in nonmyocyte cell types, 8 we sought to determine whether cardiacrestricted overexpression of TRAF2 would confer cytoprotection in the setting of IR injury ex vivo. To this end, we generated lines of transgenic mice with cardiac-restricted overexpression of TRAF2.
We obtained 3 founder lines: 329W (7 copies of TRAF2 transgene); 330W (15 copies of transgene); and 335W (24 copies of transgene; Divakaran and Mann, unpublished data). For this study, we chose the founder line with the lowest number of copies (nϭ7) of the transgene, which we refer to as MHC-TRAF2 LC . As shown in Figure 4A , TRAF2 proteins were readily detectable by Western blotting in the hearts of the MHC-TRAF2 LC mice, whereas low levels of TRAF2 were present in the LM control mice. As expected, the levels of FLAG-tagged TRAF2 proteins were readily detectable by Western blotting in the hearts of the MHC-TRAF2 LC mice. Histological analysis showed that there was no obvious myofibrillar disarray nor evidence of inflammatory cell infiltrates in the hearts of the MHC-TRAF2 LC mice compared with LM controls ( Figure 4B ). However, the heart weight-tobody weight ratio was significantly higher (PϽ0.005) in the hearts of MHC-TRAF2 LC mouse compared with those of LM controls ( Figure 4C ). Further characterization of the mice using 2D-targeted M-mode echocardiography and Millar catheterization showed that there were no significant differences in LV structure between the MHC-TRAF2 LC mice and the control mice (supplemental Figure II ). There were, however, small but significant differences in some indices of systolic and diastolic function in the MHC-TRAF2 LC mice (supplemental Figures II and III) .
To determine the effects of the cardiac-restricted overexpression of TRAF2 in the setting of IR injury, we subjected MHC-TRAF2 LC hearts to 30 minutes of no-flow ischemia followed by 30 minutes of reperfusion. Figure 5A shows that hearts from the MHC-TRAF2 LC mice had significantly (PϽ0.05/time) improved LV function recovery at 10, 20, and 30 minutes of reperfusion compared with those from the LM controls. Importantly, both the amount of myocardial CK release ( Figure 5A ) and the degree of uptake of Evans blue dye ( Figure 5B and 5C) were significantly less (PϽ0.005 and PϽ0.05, respectively) in the hearts of IR-injured MHC-TRAF2 LC compared with those of LM controls. These results suggest that TRAF2mediated signaling is cytoprotective in the setting of IR injury by preventing cardiac myocyte cell injury.
Previous studies suggest that the cytoprotective effects of TRAF2 in nonmyocytes were mediated by activation of NF-B and/or JNK. 16 To determine whether these pathways were activated in the hearts of MHC-TRAF2 LC mice (12 weeks of age), we assessed NF-B activation by electromobility gel shift assays and JNK activation using an in-gel kinase assay. As shown, in Figure 6A , the degree of NF-B activation was greater in the hearts of MHC-TRAF2 mice than in those of LM control mice at baseline, as well as after IR injury. The specificity of the DNA-protein interaction was To determine the specificity of DNAprotein binding, nuclear extracts from TRAF2 LC hearts were treated with a 20ϫ excess of unlabeled oligonucleotides and by supershift assays using polyclonal antibodies directed against the p50 and p65 components of NF-B. The positive control for the p65 supershift was obtained from a nuclear extract from a heart of a wild-type mouse that was treated with LPS at 20 mg/kg for 1 hour. B, Representative JNK activity assay in littermate and TRAF2 LC hearts (12 weeks) at baseline and after IR injury.
determined by cold-chase experiments, which showed that the labeled NF-B-DNA complexes were disrupted by a 50-fold excess of unlabeled oligonucleotide. The specificity of binding was further confirmed by supershift studies, which showed the interesting finding that the nuclear extracts from the IR hearts consisted predominantly of p50-p50 homodimers. To confirm the fidelity of the p65 antibody used for these experiments, we repeated the electromobility gel shift assays and supershift assay in LPS-treated hearts. Figure  6A shows that the p65 antibody supershifted the NF-B complexes in the LPS hearts, suggesting that the antibody that was used was robust.
Although we observed a slight increase in JNK activation in the hearts of MHC-TRAF2 mice at 4 and 8 weeks of age (data not shown), we did not observe JNK activation using the hearts of MHC-TRAF2 mice at 12 weeks of age ( Figure  6B) , consistent with the known effects of NF-B on dampening sustained JNK-mediated signaling. 17 Furthermore, JNK activity was increased to a similar degree in the LM control and TRAF2 LC mice after IR injury.
Taken together, the results of these studies suggest (but do not prove) that the cytoprotective effects of TRAF2 are mediated by NF-B rather than JNK.
Discussion
The results of this study, in which we used both gain and loss of function approaches, suggest that endogenous TNF signaling confers cytoprotection in the heart after IR injury. This study further suggests that TRAF2, a phylogenetically conserved scaffolding protein that is common to both TNFR1and TNFR2, is sufficient to confer cytoprotective responses in the heart after IR injury. Three distinct lines of evidence support these statements. First, LV functional recovery was significantly better, and the extent of LV tissue injury was significantly less after IR injury in lines of transgenic mice (MHCsTNF 3 ) with low levels of expression of TNF compared with LM control mice (Figure 1 ). Second, loss of endogenous TNF signaling in mice that were null for TNF receptor signaling resulted in significantly worse LV functional recovery and significantly greater LV tissue injury after IR injury compared with LM control mice with intact endogenous TNF receptor signaling (Figure 2) , consistent with our previous in vivo observations in TNF receptor null mice subjected to acute coronary artery occlusion. 4 To determine which TNF receptors were responsible for conveying cytoprotective responses in the heart, we subjected hearts from TNFR1 Ϫ/Ϫ or TNFR2 Ϫ/Ϫ mice to IR injury. Interestingly, both LV recovery and myocardial CK release were similar in wild-type, TNFR1 Ϫ/Ϫ , and TNFR2 Ϫ/Ϫ mice subjected to IR injury ( Figure 3A and 3B ), suggesting that signaling through either TNFR1 or TNFR2 alone is sufficient to protect adult murine cardiac myocytes after IR injury. Third, a transgenic mouse line (MHC-TRAF2 LC ) with low levels of cardiac-restricted expression of TRAF2 resulted in significantly improved LV functional recovery and significantly less LV tissue injury after IR injury compared with LM control mice with wild-type levels of endogenous TRAF2 expression ( Figure 5A ). Although the scope of this study was not intended to define the cytoprotective signaling pathways that were downstream from TRAF2-mediated signaling, our provisional results suggest an important role for p50-p50 NF-B homodimers. Insofar as p50 does not contain a transactivation domain and is therefore considered to be transcriptionally inactive, it bears emphasis that p50-p50 homodimers can inhibit transcription by displacing transcriptional activators (eg, Sp1 or p50-p65 heterodimers) from NF-B binding sites or can act as a transcriptional activator by displacing repressor transcriptional factors from NF-B binding sites. 18, 19 Additional studies will be required to determine the ensemble of cytoprotective genes that are modulated by TRAF2 activation.
Cytoprotective Effects of Tumor Necrosis Factor
The results of this study both confirm and expand on previous in vitro, 2 ex vivo, 3, 7, 20, 21 and in vivo 4 -6 studies that suggest that TNF confers cytoprotective signaling in the adult mammalian heart. Thus far, 3 mechanisms have been proposed to explain the cytoprotective effects of TNF in the heart. In models of ischemic preconditioning, it has been suggested that TNF-induced activation of the neutral sphingomyelinase pathway confers cytoprotection through generation of ceramide and/or sphingosine 1-phosphate. 5 A second mechanism that has been proposed with respect to TNF-mediated preconditioning suggests that the cytoprotective effects of TNF are mediated through activation of the Janus kinase/signal transducers and activators of transcription pathway, insofar as TNF-induced preconditioning was sensitive to pharmacological inhibition of the Janus kinase/signal transducers and activators of transcription pathway. 21 Similar results were reported recently by another group of investigators who observed decreased LV myocardial recovery postischemia as well as decreased mRNA and protein levels of STAT3 and suppressor of cytokine signaling-3 in TNFR2 Ϫ/Ϫ -deficient mice. 22 The results of this study suggest that TNF-TRAF2mediated activation of NF-B is responsible for provoking cytoprotective responses in the heart after IR injury ( Figure  6 ). Although we cannot formally exclude that TRAF2induced activation of JNK signaling contributed to the observed cytoprotection, our results suggest that this signaling pathway is downregulated in chronic TRAF2 signaling (Figure 6) , consistent with the observation that NF-B suppresses JNK signaling 23 and that the increase in JNK activation after IR injury is not different in LM control and MHC-TRAF2 LC mice (see Figure 6B ). Although our findings with respect to TRAF2-mediated activation of NF-B seem to conflict with the aforementioned studies that suggest a cytoprotective role for free radicals and/or Janus kinase/signal transducers and activators of transcription signaling, it is important to recognize that free radicals activate NF-B and that there is crosstalk between Janus kinase signaling and NF-B activation. 24, 25 Thus, it is possible the NF-B may represent a final common pathway that allows for the convergence of multiple upstream TNF-induced cytoprotective signaling pathways. Further studies will be necessary to determine whether these pathways converge on the canonical NF-B pathway that is activated through TRAF2 and whether these effects are mediated through p50-p50 homodimers.
The hypothesis that NF-B mediates the cytoprotective effects of TNF is consistent with a previous study from this laboratory, wherein we showed an increase in infarct size after acute coronary occlusion in mice harboring a dominant negative IkB␣ construct in which the critical phosphorylation (serine-32 and serine-36) and ubiquitination sites (lysine-21 and lysine-22) were removed, thereby rendering the mutant protein resistant to proteolytic degradation. 26 This point of view is also consistent with previous studies that have suggested a cytoprotective role for NF-B in hypoxic cardiac myocytes in vitro 16 and in late preconditioning in vivo. [27] [28] [29] Our findings are also consistent with a recent study, which showed that there was adverse postinfarct cardiac remodeling in mice with targeted disruption of p50. 30 Nonetheless, our findings would seem to conflict with a series of well-done studies in models of cardiac IR and/or coronary ligation, which have shown salutary effects by inhibiting NF-B, through an intracoronary infusion of a synthetic (doublestranded DNA) NF-B decoy, 31 through pharmacological inhibition of IKK␤, 32 through genomic deletion of p50, 33 or using a genetically engineered mouse that expressed a cardiac-restricted mutated dominant negative IkB␣ (Ser32Ala,Ser 36Ala, and Tyr42Phe) "3 M" construct. 34 Although the immediate explanation for these disparate views with respect to the role of NF-B in cardiac injury is not obvious, it may relate, at least in part, to differences in spatial NF-B activation in the cardiac injury models that were studied. For example, the use of oligonucleotide decoys, pharmacological inhibition of IKK␤, or genomic deletion of p50 would be expected to inhibit NF-B activation in cardiac myocytes, fibroblasts, smooth muscle cells, and endothelial cells, whereas the cardiac-restricted expression of IB␣ dominant negative would be expected to inhibit NF-B activation in cardiac myocytes alone. Thus, activation of NF-B in the vascular compartment during IR injury might result in increased influx of inflammatory cells and/or increased activation of serum proteases (eg, complement) and hence increased tissue damage that would offset the cytoprotective effects mediated by NF-B in cardiac myocytes. Furthermore, we cannot exclude the formal possibility that differences in the genetic strain of the mice used may have influenced the results.
Conclusion
In summary, the results of this study suggest that TNFmediated signaling confers cytoprotection in the heart through TRAF2-mediated activation of NF-B. Apart from the novel mechanistic insights provided by this report, the results of this study have also identified a potentially important role for TRAFs in the heart. Given that TRAF1, 2, and 6 are expressed in the heart, 35 and that TRAF proteins are involved in mediating inflammation, cell signaling, antiviral responses, and apoptosis, it is likely that TRAFs will have a variety of pleiotropic effects in the heart. Accordingly, further studies will be necessary to delineate the potentially important role that these proteins play in the heart in health and disease.
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